Metabolites of Tramadol in the Postoperative Surgical Patients

Completed

Conditions: Renal Failure
Abdominal Surgery
Respiratory Failure
Liver Dysfunction
Multiorgan Failure

Interventions: Drug: Postoperative analgesia using tramadol

Registration Number: NCT04004481

Lead Sponsor: Osijek University Hospital

Brief Summary: Tramadol is opioid analgesic widely used to treat moderate to severe pain. It is metabolized by cytochrome CYP2D6 into two major metabolites: pharmacologically active metabolite O-desmethyltramadol (M1) and inactive N-desmethyltramadol (M2), respectively. Tramadol kinetics in a population of patients undergoing major abdominal surgical procedures, and in patients with a greater or lesser degree of organic failure, is still not well researched. The investigators will measure plasma concentrations of tramadol and its metabolites after usual tramadol doses in ICU patients after major abdominal surgery. Also analgesic affect and side effect of tramadol will be recorded.

Detailed Description: The blood samples for the CYP2D6 gene polymorphism analysis will be taken from all patients included in the study. The patients will be categorized as slow (PM), normal (NM) or ultra-fast metabolizers (UM) of tramadol using analysis of the CYP2D6 phenotype. Standard laboratory findings including red blood cells, urea, creatinine, and cholinesterase will be done before surgery.

The patients will receive 500 mg of tramadol intravenously divided into 5 doses during the first 24 postoperative hours in the ICU. The plasma concentrations of tramadol, O-desmethyltramadol and N-desmethyltramadol will be measured 1, 2 and 4 hours after the first dose, and immediately before the 2nd, 3rd and 5th dose. There will therefore be 6 measurements of tramadol and its metabolites.

The analgesic effect of tramadol will be measured in awake patients with Numeric Rating Scale - NRS (0 - without pain, 10 - strong pain) 30 minutes before and 30 minutes after tramadol administration. The NRS value of 3 or less will be considered as adequate analgesia. In case of inadequate analgesia rescue analgesic (morphine) will be used according to the local protocol.

In unconscious patients the analgesic effect of tramadol will be tested by Critical Care Pain Observation Tool (CPOT). The CPOT value of less than 2 will be considered as adequate analgesia. In case of inadequate analgesia rescue analgesic (morphine) will be used according to the local protocol. During the first 24 hours side effect of tramadol, such as nausea, vomiting and new respiratory depression will be recorded.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 50

Inclusion Criteria

patients after major abdominal surgery will be observed.
surgical interventions requiring a laparotomy and involving resection of the organs of the digestive system
postoperative ICU admission.

Exclusion Criteria

allergic reaction to tramadol
patients under 18 years old
patient over 90 years old
BMI <18 and >35
laparoscopic surgery
chronic therapy with tramadol, cimetidine, paroxetine, pimozide, metoclopramide, amiodarone, olanzapine, chlorpromazine, fluphenazine, haloperidol, thioridazine, risperidone and clozapine

Study & Design

Study Type: OBSERVATIONAL

Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Adult patients undergoing major open abdominal surgery	Postoperative analgesia using tramadol	Observational study. In the patients undergoing major open abdominal surgery for cancer tramadol will be used for postoperative analgesia. In the postoperative period parent compound and metabolites of tramadol will be measured. Postoperative analgesia and adverse effects will be registered and compared between CYP2D6 phenotypes observed.

Primary Outcome Measures

Name	Time	Method
Serum Concentration of Tramadol and Tramadol Metabolites With Respect to Metabolic Phenotype	1, 2, and 4 hours after first dose and immediately before 2nd, 3rd, and 5th dose, up to 24 hours	The plasma concentrations of tramadol, O-desmethyltramadol (ODT) and N-desmethyltramadol (NDT) will be measured 1, 2 and 4 hours after the first dose of 100 mg tramadol i.v., and immediately before the 2nd, 3rd and 5th dose. There will therefore be 6 measurements of tramadol and its metabolites.

Secondary Outcome Measures

Name	Time	Method
Length of ICU Stay	Up to 6 months	Length of stay in ICU will be recorded and correlated with standard laboratory values and tramadol and metabolites concentration.
Number of Participants With Nausea and Vomiting After Tramadol	Nausea and vomiting was assessed during first 30 minutes after tramadol administration	Nausea and/or vomiting during treatment with tramadol in ICU will be recorded.
Number of Patients With Respiratory Depression After Tramadol	Respiratory depression was observed up to 30 minutes after tramadol administration	Respiratory depression after tramadol is considered to be any drop in saturation below 90% or drop in respiratory rate below 10/min.
Analgesic Effect of Tramadol Measured by Numeric Rating Scale (NRS)	Before each dose of tramadol and 30 minutes after tramadol dose, up to 24 hours	The analgesic effect of tramadol will be measured in awake patients with Numeric Rating Scale (NRS, 0 - without pain, 10 - the worst pain) 30 minutes before and 30 minutes after tramadol administration. The NRS value of 3 or less will be considered as adequate analgesia. In case of inadequate analgesia morphine will be used according to the local protocol.
Analgesic Effect of Tramadol Measured by Critical Care Pain Observation Tool (CPOT)	Pain was assessed before and 30 minutes after each tramadol dose, up to 24 hours.	In unconsciousness patents, the analgesic effect of tramadol will be tested by Critical Care Pain Observation Tool (CPOT). Highest score on a scale is 8 (worst pain) and lowest is 0 (no pain). The CPOT value of less than 2 will be considered as adequate analgesia.